JAZZ PHARMACEUTICAL (J7Z BE) stock market data APIs
€138.5742
0(0%)
as of December 12, 2025
Try our APIs with
free plan!
JAZZ PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for J7Z.BE.
Prev. Close
138.5742
Open
138.5742
High
138.5742
Low
138.5742
52 wk Range
86.72-154.8
Market Cap
6 680 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JAZZ PHARMACEUTICAL data using free add-ons & libraries
Get JAZZ PHARMACEUTICAL Fundamental Data
JAZZ PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JAZZ PHARMACEUTICAL News
New
3 Value Stocks We’re Skeptical Of
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook
Jazz Pharmaceuticals' fair value estimate has nudged up from $206.38 to $208.50 per share as analysts recalibrate their models around stronger long term growth prospects, particularly tied to the Ziih...
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have added about 24.5% in that time frame, outperforming the S&P 500. Will the recent positive trend c...
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
